Intervention/Treatment: The study tests the drug Dupilumab, administered subcutaneously, alongside a non-sedative antihistamine and a moisturizer. Dupilumab is designed to reduce inflammation and ...

Sanofi is currently conducting a Phase 3 clinical trial to evaluate the safety and effectiveness of a new 21-valent pneumococcal conjugate vaccine (PCV21) in healthy infants and toddlers. The study, ...

Sanofi (ENXTPA:SAN) has made a move that is bound to get investors talking, as shares edged up just over 5% in the past week. While there is no headline-making event at play, this uptick arrives after ...

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why SNY stock is a strong buy.

Sanofi's Tzield is now the first and only disease-modifying therapy to be approved for type 1 diabetes (T1D) in the UK.

[PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology to streamline their development. The French drugmaker will pay US$1.15 ...

Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson , to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli.

Sanofi shares were down 3% at 1107 GMT, having earlier fallen as much as 5.2% to their lowest since mid-November with JP Morgan analysts saying investors had expected a better 2023 outlook and a ...

French drug maker Sanofi dismissed Chief Executive Christopher Viehbacher less than 24 hours after the German-Canadian executive played down speculation over his departure.

Sanofi is committing up to $60 million to Gyroscope Therapeutics, a clinical-stage biotech whose lead program could become the first gene therapy for a particular vision loss disorder.